Paul Fortin

Dr. Fortin joined the staff of Toronto Western Division/University Health Network (UHN) and Research Institute in 2000 as a Clinician Scientist and Director of Clinical Research for the Arthritis Centre of Excellence. He became Full Professor of Medicine at the University of Toronto in 2007 and held cross-appointments as staff at the Hospital for Sick Children and as Associate Professor at the Institute of Medical Sciences and the Department of Health Policy, Management and Evaluation of the University of Toronto. In August 2011, he moved to Quebec City, Canada and became Full Professor with tenure at Université Laval and Clinician-Scientist at the ‘Centre de Recherche du Centre Hospitalier Universitaire de Québec’. He’s held a senior Canada Research Chair on Systemic Autoimmune Rheumatic Diseases since 2012. 

Dr. Fortin has been working on a better understanding of the bio-psycho-social impact of chronic rheumatic diseases such as systemic lupus erythematosus (SLE), the antiphospholipid antibody syndrome (APS), systemic autoimmune rheumatic diseases (SARD) and rheumatoid arthritis. He is particularly interested in clinical applications of translational research and in developing interventions for the treatment of SLE, APS and SARD.

His methodological interests cover the development and validation of health status measures and other clinical tools such as measures of disease activity or damage in SLE. His other methodological interests include the development of risk profiles for arterial or venous thrombosis in APS, the testing of treatments of disease activity or cardiovascular disease in SLE, or the validation of biological markers in SLE and SARD.

In 1995, he created the Canadian Network for Improved Outcomes in SLE (CaNIOS) with the specific goal of running a multi-centre, randomized, and controlled Study of Methotrexate in Lupus Erythematosus (SMILE).  CaNIOS brought together many lupus experts who, despite their limited individual cohorts, were able to pool information for the completion of SMILE.  CaNIOS has conducted several CIHR and TAS funded national studies, including the project on ‘Empowering Patients as Active Partners in Their Care: Lupus Interactive Navigator (LIN)’, ‘The Dissemination of the Lupus Health Passport’, ‘Health Improvement and Prevention Program for Persons with SLE’ (HIPP study), ‘Lupus Nephritis New Emerging Team’ (LuNNET), ‘Genetic and Environmental Factors in SLE’ (GenES Study), and ‘Role of Thrombophilic Factors in Persons with SLE’ (ThromboFIL study). Also, CaNIOS is building a national database, a clinical trial infrastructure through support from the Lupus Clinical Trial Consortium and a training environment for young researchers.

Since 2011, Dr. Fortin is building an arthritis multidisciplinary research infrastructure based on the SARD Database and Biobank hosted by Université Laval and that has been a catalyst for translational research on SLE and rheumatoid arthritis locally and nationally. His efforts have culminated in the recent creation of the Centre ARThrite, which is one of the few scientific centres recognized and supported by Université Laval. 

Dr. Fortin received the Kirkland Scholar Award in 2007, and he received the prestigious Distinguished Senior Research Investigator Award from The Arthritis Society of Canada. In 2010, he received the Hope Award from the Lupus Ontario to recognize his outstanding leadership in improving the lives of people with lupus. He received the Distinguished Investigator Award of the Canadian Rheumatology Association in 2020. 

 

Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB, Gladman D, Nived O, Romero-Diaz J, Petri M, Ginzler E, Fortin PR, Bae SC, Wallace DJ, Yelin EH, Bernatsky S. Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment. Lupus. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28595511

 

Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, Bernatsky S, Bruce I, Buyon J, Cervera R, Clarke A, Dooley MA, Fortin P, Ginzler E, Gladman D, Hanly J, Inanc M, Jacobsen S, Kamen D, Khamashta M, Lim S, Manzi S, Nived O, Peschken C, Petri M, Kalunian K, Rahman A, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K, Sturfelt G, Urowitz M, van Vollenhoven R, Wallace DJ, Zoma A, Merrill J, Gordon C (2017) A study of flare assessment in systemic  lupus erythematosus (SLE) based on paper patients. Arthritis Care Res (Hoboken). [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28388813

 

Choi MY, Clarke AE, St. Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Buyon J, Mahler M, Fritzler MJ (2017) The Prevalence and Determinants of Anti-DFS70 Autoantibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients. Lupus, 0: 1-9. https://www.ncbi.nlm.nih.gov/pubmed/28420054

 

Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Huq M, Proudman S, Nikpour M; Canadian Scleroderma Research Group*; Australian Scleroderma Interest Group (2017) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis & Rheumatology, 69(5):1067-1077. https://www.ncbi.nlm.nih.gov/pubmed/28029745

 

Richard N, Hudson M, Gyger G, Baron M, Sutton E, Khalidi N, Pope JE, Carrier N, Larché M, Albert A, Fortin PR, Thorne C, Masetto A; on the behalf of Canadian Scleroderma Research Group* (2017) Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology (Oxford). 56(4):581-588. https://www.ncbi.nlm.nih.gov/pubmed/28013205

 

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE (2017) Breast cancer in systemic lupus. Lupus, 26(3): 311-315. https://www.ncbi.nlm.nih.gov/pubmed/27687028

 

Li G, Adachi JD, Cheng J, Thabane L, Hudson M, Fritzler MJ, Lorenzi S, Baron M, Larché M; Canadian Scleroderma Research Group* (2017) Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28229818

 

Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Harcourt D, Rumsey N, Mayes MD, Assassi S, Körner A, Fox RS, Gholizadeh S, Mills SD, Fortune C, Thombs BD; SPIN^∆ Investigators (2017) Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 20: 99-106. https://www.ncbi.nlm.nih.gov/pubmed/28068643

 

Levis AW, Harel D, Kwakkenbos L, Carrier ME, Mouthon L, Poiraudeau S, Bartlett SJ, Khanna D, Malcarne VL, Sauve M, van den Ende CH, Poole JL, Schouffoer AA, Welling J, Thombs BD; and the Scleroderma Patient-Centered Intervention Network^∆ Investigators (2016) Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res (Hoboken), 68(11):1704-1713. https://www.ncbi.nlm.nih.gov/pubmed/27015290

 

Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, Molnar JC, Rice DB, Thombs BD; and the SPIN^∆ Investigators (2016) Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Clinical and Experimental Rheumatology, 34 Suppl 100(5): 92-99. https://www.ncbi.nlm.nih.gov/pubmed/27494308

 

Riehm KE, Kwakkenbos L, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Nielsen K, Baron M, Frech T, Hudson M, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, Thombs BD; Scleroderma Patient-Centered Intervention Network^∆ Investigators (2016) Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care & Research (Hoboken), 68(8): 1195-200. https://www.ncbi.nlm.nih.gov/pubmed/26619042

 

Hudson M, Luck Y, Stephenson M, Choi MY, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group* (CSRG) (2016) Anti-HMGCR antibodies in systemic sclerosis. Medicine (Baltimore), 95(44): e5280. https://www.ncbi.nlm.nih.gov/pubmed/27858897

 

Leclair V, Regardt M, Wojcik S, Hudson M; Canadian Inflammatory Myopathy Study^± (CIMS) (2016) Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS One, 9; 11(8):e0160753. https://www.ncbi.nlm.nih.gov/pubmed/27504827

 

Landolt-Marticorena C, Prokopec SD, Morrison S, Noamani B, Bonilla D, Reich H, Scholey J, Avila-Casado C, Fortin PR, Boutros PC, Wither J. (2016) A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Research & Therapy, 4; 18(1): 218. https://www.ncbi.nlm.nih.gov/pubmed/27716443

 

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V (2016) A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis & Rheumatology, 68(8):1932-44. https://www.ncbi.nlm.nih.gov/pubmed/26991067

 

Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin PR, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford), 55(2): 252-62. https://www.ncbi.nlm.nih.gov/pubmed/26342222

 

Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group* (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS) (2016) Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore), 95(35): e4713. https://www.ncbi.nlm.nih.gov/pubmed/27583908

 

Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD; Canadian Scleroderma Research Group* (2016) Development and Validation of the Body Concealment Scale for Scleroderma. Arthritis Care & Research (Hoboken), 68(8): 1158-1165. https://www.ncbi.nlm.nih.gov/pubmed/26663624

 

Levis B, Rice DB, Kwakkenbos L, Steele RJ, Hagedoorn M, Hudson M, Baron M, Thombs BD; Canadian Scleroderma Research Group* (2016) Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. Arthritis Care & Research (Hoboken), 68(8): 1143-1149. https://www.ncbi.nlm.nih.gov/pubmed/26605870

 

Valenzuela A, Baron M, Canadian Scleroderma Research Group*, Herrick AL, Proudman S, Stevens W; Australian Scleroderma Interest Group, Rodriguez-Reyna TS, Vacca A, Medsger TA Jr, Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L (2016) Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars in Arthritis and Rheumatism, 46(3): 344-349. https://www.ncbi.nlm.nih.gov/pubmed/27371996

 

Baron M, Pope J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larché M, Abu-Hakima M, Rodriguez-Reyna TS, Cabral-Castaneda AR, Fritzler MJ, Wang M, Hudson M (2016) Calcinosis is associated with digital ischaemia in systemic sclerosis: a longitudinal study. Rheumatology (Oxford), 55(12): 2148-2155. https://www.ncbi.nlm.nih.gov/pubmed/27593964

 

Fortin PR, Cloutier N, Bissonnette V, Aghdassi E, Eder L, Simonyan D, Laflamme N, Boilard E (2016) Distinct Subtypes of Microparticle-containing Immune Complexes Are Associated with Disease Activity, Damage, and Carotid Intima-media Thickness in Systemic Lupus Erythematosus. Journal of Rheumatology, 43(11): 2019-2025. https://www.ncbi.nlm.nih.gov/pubmed/27585687

 

Harel D, Hudson M, Iliescu A, Baron M, Canadian Scleroderma Research Group*, Steele R (2016) Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician’s Global Assessment of Disease Severity in Systemic Sclerosis. Journal of Rheumatology, 43(8): 1510-1518. https://www.ncbi.nlm.nih.gov/pubmed/27307525

 

Neville C, Da Costa D, Rochon M, Peschken CA, Pineau CA, Bernatsky S, Keeling S, Avina-Zubieta A, Lye E, Eng D, Fortin PR (2016) Development of the Lupus Interactive Navigator as an Empowering Web-Based eHealth Tool to Facilitate Lupus Management: Users Perspectives on Usability and Acceptability. JMIR Research Protocols, 5(2):e44. https://www.ncbi.nlm.nih.gov/pubmed/27240666

 

George A, Wong-Pak A, Peschken CA, Silverman E, Pineau C, Smith CD, Arbillaga H, Zummer M, Bernatsky S, Hudson M, Hitchon C, Fortin PR, Nevskaya T, Pope JE, 1000 Faces of Lupus Investigators (2016) The influence of education on disease activity and damage in systemic lupus erythematous: Data from the 1000 Canadian Faces of Lupus. Arthritis Care & Research (Hoboken), 69(1): 124-132. https://www.ncbi.nlm.nih.gov/pubmed/27110869

 

Boilard E, Fortin PR (2016) Connective tissue diseases: Mitochondria drive NETosis and inflammation in SLE. Nature Reviews Rheumatology, 12(4): 195-196. https://www.ncbi.nlm.nih.gov/pubmed/26935279

 

Widdifield J, Moura CS, Wang Y, Abrahamowicz M, Paterson JM, Huang A, Beauchamp ME, Boire G, Fortin PR, Bessette L, Bombardier C, Hanly JG, Feldman D, Bernatsky S, CAnadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM) (2016) The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. The Journal of Rheumatology, 43(5): 861-868. https://www.ncbi.nlm.nih.gov/pubmed/26879353

 

Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler BF, Petri M, Bruce IN, Khamashta M, Aranow C, Dooley M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian KC, Ỉnanç M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T (2016) Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Science & Medicine, 3(1):e000143. Erratum in: Lupus Science & Medicine. 3(1):e000143corr1. https://www.ncbi.nlm.nih.gov/pubmed/27099765

 

Bernatsky S, Smargiassi A, Barnabe C, Svenson LW, Brand A, Martin RV, Hudson M, Clarke AE, Fortin PR, van Donkelaar A, Edworthy S, Bélisle P, Joseph L (2016) Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. Environmental Research, 146: 85-91. https://www.ncbi.nlm.nih.gov/pubmed/26724462

 

Racine M, Hudson M, Baron M, Nielson WR, Canadian Scleroderma Research Group* (2016) The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. Journal of Pain and Symptom Management, 52(1): 43-53. https://www.ncbi.nlm.nih.gov/pubmed/26876159

 

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group* (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Baron M, Fritzler MJ (2015) Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity, 48(8): 542-551. https://www.ncbi.nlm.nih.gov/pubmed/26334795

 

Kwakkenbos L, Minton O, Stone PC, Alexander S, Baron M, Hudson M, Thombs BD; Canadian Scleroderma Research Group* (2015) Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. The Journal of Rheumatology. 42(7): 1156-1162. https://www.ncbi.nlm.nih.gov/pubmed/26034154

 

Srivastava N, Hudson M, Tatibouet S, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group* (CSRG) (2015) Thinking outside the box–The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Seminars in Arthritis and Rheumatism, 45(2): 184-189. https://www.ncbi.nlm.nih.gov/pubmed/25959492

 

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ, Canadian Scleroderma Research Group* (CSRG), Australian Scleroderma Cohort Study (ASCS), Genetics versus Environment in Scleroderma Outcome Study (GENISOS) (2015) Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clinical and Experimental Rheumatology, 33(4 Suppl 91): S131-135. https://www.ncbi.nlm.nih.gov/pubmed/26315678

 

Moura CS, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Boire G, Fortin PR, Bessette L, Bombardier C, Widdifield J, Hanly JG, Feldman D, Maksymowych W, Peschken C, Barnabe C, Edworthy S, Bernatsky S; CAN-AIM (2015)  Early medication use in new-onset rheumatoid arthritis may delay joint replacement:  results of a large population-based study. Arthritis Research & Therapy, 17: 197. https://www.ncbi.nlm.nih.gov/pubmed/26235697

 

Al Dhanhani AM, Gignac MA, Beaton DE, Su J, Fortin PR (2015) Job Accommodations Availability and Utilization Among People with Lupus:  An Examination of Workplace Activity Limitations and Work Context Factors. Arthritis care & research (Hoboken), 67(11): 1536-1544. https://www.ncbi.nlm.nih.gov/pubmed/26214148

 

Bruce IN, O’Keefe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven RF, Kalunian KC, Ruis-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB (2015)  Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.  Annals of the Rheumatic Diseases, 74(9): 1706-1713. https://www.ncbi.nlm.nih.gov/pubmed/24834926

 

Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, Bruce IN (2015) Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.  Annals of the Rheumatic Diseases, 74(8): 1530-1536. https://www.ncbi.nlm.nih.gov/pubmed/24692585

 

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2015) Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis & Rheumatology, 67(7): 1837-47. https://www.ncbi.nlm.nih.gov/pubmed/25778456

 

Bernatsky S, Smargiassi A, Johnson M, Kaplan GG, Barnabe C, Svenson L, Brand A, Bertazzon S, Hudson M, Clarke AE, Fortin PR, Edworthy S, Belisle P, Joseph L (2015) Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environmental Research, 140: 474-478. https://www.ncbi.nlm.nih.gov/pubmed/25988990

 

*  Dr. Paul R. Fortin is member of the Canadian Scleroderma Research Group (CSRG)

± Dr. Paul R. Fortin is member of the Canadian Inflammatory Myopathy Study (CIMS)

£ Dr. Paul R. Fortin is member of the CANadian Rheumatology Administrative Data Network (CANRAD)

≠ Dr. Paul R. Fortin is member of Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS)

∆ Dr. Paul R. Fortin is member of the Scleroderma Patient-Centered Intervention Network (SPIN)